However, it required 1–3 μΜ dose to effectively inhibit signaling in RASMUT/BRAFWT melanoma or lung cancer cells, suggesting some resistance due to RAF priming similarly to other αC-IN inhibitors11,12 (Fig. 4a). The gene discussed is RAF1; the disease is melanoma.